Using antidepressants during pregnancy: An update

Psychiatric Times

Volumn 23, Issue 9, 2006, Pages 90-95

  King, Elizabeth Z ^a   Stowe, Zachary N ^a,b   Newport, D Jeffrey ^a,b  

^a Department of Psychiatry and Behavioral Sciences ^*

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845781119     PISSN: 08932905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. O'Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Psychol. 1984;93:158-171.
2. Affonso DD, Lovett S, Paul SM, et al. A standardized interview that differentiates pregnancy and postpartum symptoms from perinatal clinical depression. Birth. 1990;17:121-130.
3. Beck CT. Screening methods for postpartum depression. J Obstet Gynecol Neonatal Nurs. 1995;24:308-312.
4. Weissman MM, Olfson M. Depression in women: implications for health care research. Science. 1995;269:799-801.
5. Evans J, Heron J, Francomb H, et al. Cohort study of depressed mood during pregnancy and after childbirth. BMJ. 2001;323:257-260.
6. Stowe ZN, Hostetter AL, Newport DJ. The onset of postpartum depression: implications for clinical screening in obstetrical and primary care. Am J Obstet Gynecol. 2005;192:522-526.
7. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295:499-507.
8. Bledsoe SE, Grote NK. Treating depression during pregnancy and the postpartum: a preliminary meta-analysis focused on research and timing. Res Soc Work Pract. 2006;16:109-120.
9. Zuckerman B, Amaro H, Bauchner H, Cabral H. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol. 1989;160:1107-1111.
10. Jesse DE, Graham M, Swanson M. Psychosocial and spiritual factors associated with smoking and substance use during pregnancy in African American and White low-income women. J Obstet Gynecol Neonatal Nurs. 2006;35:68-77.
11. Steer RA, Scholl TO, Hediger ML, Fischer RL. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol. 1992;45:1093-1099.
12. Orr ST, James SA, Blackmore-Prince C. Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. Am J Epidemiol. 2002;156:797-802.
13. Chung TK, Lau TK, Yip AS, et al. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med. 2001;63:830-834.
14. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002;159:1889-1895.
15. Luoma I, Tamminen T, Kaukonen P, et al. Longitudinal study of maternal depressive symptoms and child well-being. J Am Acad Child Adolesc Psychiatry. 2001;40:1367-1374.
16. O'Connor TG, Heron J, Glover V; ALSPAC Study Team. Antenatal anxiety predicts child behavioral/emotional problems independently of postnatal depression. J Am Acad Child Adolesc Psychiatry. 2002;41:1470-1477.
17. O'Connor TG, Heron J, Golding J, Glover V; ALSPAC Study Team. Maternal antenatal anxiety and behavioural/emotional problems in children: a test of a programming hypothesis. J Child Psychol Psychiatry. 2003;44:1025-1036.
18. Sondergaard C, Olsen J, Friis-Hasche E, et al. Psychosocial distress during pregnancy and the risk of infantile colic: a follow-up study. Acta Paediatr. 2003;92:811-816.
19. Huot RL, Brennan PA, Stowe ZN, et al. Negative affect in offspring of depressed mothers is predicted by infant cortisol levels at 6 months and maternal depression during pregnancy, but not postpartum. Ann N Y Acad Sci. 2004;1032:234-236.
20. Jones NA, Field T, Fox NA, et al. EEG activation in 1-month-old infants of depressed mothers. Dev Psychopathol. 1997;9:491-505.
21. Newport DJ, Stowe ZN, Nemeroff CB. Parental depression: animal models of an adverse life event. Am J Psychiatry. 2002;159:1265-1283.
22. Rimm AA, Katayama AC, Diaz M, Katayama KP. A meta-analysis of controlled studies comparing major malformation rates in IVF and ICSI infants with naturally conceived children. J Assist Reprod Genet. 2004;21:437-443.
23. Swedish Centre for Epidemiology. Registration of congenital malformations in the Swedish Health Registers, 1995-2001. 2004. Available at: http://www.sos.se/epc/english. Accessed June 30, 2006.
24. New York State Department of Health. Congenital Malformations Registry Summary Report: Statistical Summary of Children Born in 1998-2001 and Diagnosed Through 2003. 2005. Available at: http://www.health.state.ny.us/nysdoh/cmr/docs/ 98report.pdf. Accessed June 27, 2006.
25. GlaxoSmithKline. Epidemiology study: Updated preliminary report on bupropion and other antidepressants, including paroxetine in pregnancy and the occurrence of cardiovascular and major congenital malformation (Study EPIP083). 2005. Available at: http://ctr.gsk.co.uk/summary/paroxetine/epip083part2.pdf. Accessed June 30, 2006.
26. US Food and Drug Administration. Paroxetine hydrochloride (marketed as Paxil) information. FDA alert (12/2005): increase in the risk of birth defects. 2005. Available at: http://www.fda.gov/cder/drug/infopage/paroxetine/default. htm. Accessed June 30, 2006.
27. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993;269:2246-2248.
28. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010-1015.
29. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159:2055-2061.
30. Chun-Fai-Chan B, Koren G, Fayez I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol. 2005;192:932-936.
31. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279:609-610.
32. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001;158:1728-1730.
33. Einarson A, Bonari L, Voyer-Lavigne S, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry. 2003;48:106-110.
34. Sivojelezova A, Shuhaiber S, Sarkissian L, et al. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol. 2005;193:2004-2009.
35. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293:2372-2383.
36. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579-587.
37. Greenough A, Khetriwal B. Pulmonary hypertension in the newborn. Paediatr Respir Rev. 2005;6:111-116.
38. Misri S, Oberlander TF, Fairbrother N, et al. Relation between prenatal maternal mood and anxiety and neonatal health. Can J Psychiatry. 2004;49:684-689.
39. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997;336:258-262.
40. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;142:402-408.
41. Black MM, Matula K. Essentials of Bayley Scales of Infant Development-II Assessment. New York: Wiley; 2000.
42. Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry. 2004;65:230-237.
43. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect. 1998;30:24-29, 46.
44. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365:482-487.
45. Wisner KL, Perel JM, Peindl KS, et al. Prevention of recurrent postpartum depression: a randomized clinical trial. J Clin Psychiatry. 2001;62:82-86.
46. Wisner KL, Perel JM, Peindl KS, et al. Prevention of postpartum depression: a pilot randomized clinical trial. Am J Psychiatry. 2004;161:1290-1292.
47. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol. 1997;89:713-718
48. Wilton LV, Pearce GL, Martin RM, et al. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol. 1998;105:882-889.
49. Briggs GG, Freeman RK, Yaffe SJ. Results of Michigan Medicaid Surveillance Study 1985-1992. In: Drugs in Pregnancy and Lactation. 7th ed. Baltimore: Lippincott Williams & Wilkins: 2005.
50. Hallberg P, Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breastfeeding: a review and clinical aspects. J Clin Psychopharmacol. 2005;25:59-73.
51. Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther. 2002;72:184-191.
52. McElhatton PR, Garbis HM, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol. 1996;10:285-294.
53. Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol. 2003;59:767-773.
54. GlaxoSmithKline. Bupropion pregnancy registry, interim report, September 1, 1997 through August 31, 2005. Wilmington, NC: GlaxoSmithKline; 2006.
55. Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol. 2003;188:812-815.
56. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156:1129-1132.
57. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60:720-726.
58. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158:312-316.
59. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics. 2004;113:368-375.